Overview

This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis

Status:
Completed

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

The primary objective is to estimate global response rate. Clinical, microbiological and global response rates and its 95% confidence intervals will be computed. No hypotheses will be tested.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Treatments:

Anidulafungin
Echinocandins
Voriconazole